Table 1: Background of enrolled patients.
|Number of patients received iBCG therapy||555 cases|
|Male/Female ratio||438/117 cases|
|Mean age ± SD (years)||72 ± 10|
|T stage of bladder cancer (Tis/Ta/T1/T2)||158/209/158/30 cases|
|Cellular atypism (G1/G2/G3)||146/283/126 cases|
iBCG: intravesical Bacillus Calmette-Guerin; Tis: carcinoma in situ; Ta: noninvasive papillary cancer; T1: invasion to submucosa; T2: invasion to muscle layer; G1: low-grade; G2: lowgrade and high-grade; G3: high-grade cancer.